Rapid antibody response induced by mRNA COVID vaccines in mice – News-Medical.Net

We use cookies to enhance your experience. By continuing to browse this site you agree to our use of cookies. More info.
The COVID-19 vaccines are unique not only for their fast development or excellent response in preventing severe COVID-19 infection but also for the novel use of mRNA technology in a vaccine. Though, questions have been raised on how mRNA technology works to boost the immune system.
A new study posted in the bioRxiv* preprint server used mouse models to investigate how mRNA vaccines elicit a rapid antibody response. Their findings show two different mRNA vaccines successfully boost antibody levels — IL-5, IL-6, and MCP-1 —5 days after administration.
“The rapid immune kinetics of mRNA vaccines can be an advantageous property that makes them well suited for rapid control of infectious disease outbreaks,” concluded the researchers.
The team studied antibody levels of C57BL/6 mice who were vaccinated with mRNA vaccines expressing the SARS-CoV-2 spike protein at either 1 µg (low) or 4 µg (high) doses. The vaccines were given through the muscle or through the skin.
Other groups of mice serving as control groups were vaccinated intramuscularly with a DNA vaccine.
Using an ELISA assay, the researchers were able to measure the number of spike-specific binding antibodies present in mice.
After 5 days of immunization, mice that were given the 4 µg dose of the mRNA vaccine showed increased spike-specific binding antibody titers. Though antibody titers were much higher with vaccines given intradermally than intramuscularly.
In contrast, antibody titers were not detectable with the DNA vaccine or the low-dose mRNA vaccine.
After a week since vaccination, mice immunized intramuscularly with a high-dose mRNA vaccine continued to show significantly higher antibody titers compared to mice given the DNA vaccine.
At 2 weeks, all mice administered an mRNA vaccine showed dose-dependent antibody responses. In the DNA vaccine group, antibody titers were detectable but lower than the mRNA vaccine group.
After 3 weeks, antibody titers from the DNA vaccine were similar to those observed in mice given the high-dose mRNA vaccine.
The results suggest mRNA vaccines produce rapid antibody responses that are dose and route-dependent.
Mice given a high-dose mRNA vaccine showed neutralizing antibody titers 5 days after immunization. Mice who received the vaccine through the skin showed the highest neutralizing antibody titers.
After 1 week, mice who were given the mRNA vaccine through the muscle showed significantly higher neutralizing antibody titers than mice with the DNA vaccine. But after 3 weeks, neutralizing antibody levels produced from the DNA vaccine were similar to those produced from the mRNA vaccine.
Next, the research team explored vaccinations’ effects on cytokine and chemokine expression in both types of vaccines. Specifically, they studied immune responses from mice given either a high-dose mRNA vaccine or a high-dose DNA vaccine administered intramuscularly.
Cytokines that are critical for the development of B cells and antibody production were significantly elevated after mRNA vaccination.
IL-5 — a cytokine involved in B cell differentiation to antibody-secreting plasma cells in mice — was significantly higher in mRNA vaccinated mice than in DNA vaccinated mice as early as 5 hours after immunization.
IL-6 — a cytokine needed for B cell proliferation and isotype switching — showed elevated levels 5 hours after mRNA vaccination compared to DNA vaccination.
Major players for antigen-presenting cell activation and migration, including chemokines MCP-1, MIP-1ɑ, MIP-1β, and IP-10 were boosted 5 to 24 hours after mRNA vaccination.
Could mRNA vaccines work for other viruses beyond SARS-CoV-2? The researchers looked into this question by injecting an mRNA vaccine that had the Clade C 459C HIV-1 envelope gp140. For comparison purposes, they also administered a DNA vaccine, a purified protein vaccine, and a rhesus adenovirus 52 vaccine with the same HIV antigen. All vaccines were given intramuscularly.
Three days since the mRNA vaccination, the research team detected low antibody titers. But after 5 days, robust antibody responses were observed.
During this timeframe, all other non-mRNA vaccines did not elicit antibody responses.
At 3 weeks since immunization, all four vaccines showed similar and robust antibody titers.
The results indicate mRNA vaccines produce a more rapid immune response than other vaccine technologies. Additionally, mRNA vaccines have the potential for use in other infectious diseases.
medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.
Posted in: Drug Trial News | Medical Science News | Medical Research News | Disease/Infection News
Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
Written by
Jocelyn Solis-Moreira graduated with a Bachelor's in Integrative Neuroscience, where she then pursued graduate research looking at the long-term effects of adolescent binge drinking on the brain's neurochemistry in adulthood.
Please use one of the following formats to cite this article in your essay, paper or report:
Solis-Moreira, Jocelyn. (2021, November 07). Rapid antibody response induced by mRNA COVID vaccines in mice. News-Medical. Retrieved on November 10, 2021 from
Solis-Moreira, Jocelyn. "Rapid antibody response induced by mRNA COVID vaccines in mice". News-Medical. 10 November 2021. <>.
Solis-Moreira, Jocelyn. "Rapid antibody response induced by mRNA COVID vaccines in mice". News-Medical. (accessed November 10, 2021).
Solis-Moreira, Jocelyn. 2021. Rapid antibody response induced by mRNA COVID vaccines in mice. News-Medical, viewed 10 November 2021,
Cancel reply to comment
Professor Jorge Ruas
News-Medical speaks to Professor Jorge Ruas about how he has identified an important protein involved in motor coordination.
Dr. Tanya Altmann
News-Medical speaks to Dr. Tanya Altmann about her latest partnership with Duracell that is encouraging people to learn about lithium coin battery safety.
Dr. Jonathan Lifshitz
In this interview, we spoke to Dr. Jonathan Lifshitz about his latest research into traumatic brain injuries and how they can affect an unborn child's development.
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.
This website is certified by Health On the Net Foundation. Click to verify.This site complies with the HONcode standard for trustworthy health information: verify here.
AZoNetwork – An AZoNetwork Site
Owned and operated by AZoNetwork, © 2000-2021